Letu

What Letu does

Letu (乐土生命科技), formally Shenzhen Letu Life Science Investment Co., Ltd., is a privately held precision medicine and biopharmaceutical company founded in 2016 in Shenzhen, China. The company operates a multi-platform portfolio spanning biologics contract development and manufacturing (CDMO), molecular and consumer genetic testing, cell storage and stem cell services, integrated medical services, and a high-end medical-wellness resort. It serves three primary customer groups: domestic and international biotech and biopharma companies requiring large-scale biologics manufacturing; cancer patients and at-risk individuals seeking molecular diagnostics and genetic testing; and affluent consumers pursuing preventive health management, longevity services, and stem cell storage. The company is led by Founder/Chairman Liu Ruyin, with Nobel Laureate James Watson serving as Scientific Chief Advisor and Lifetime Honorary Chairman, and has been recognized as a Chinese unicorn enterprise for four consecutive years (2022-2025).

The company's core technology is biologics CDMO, where it was the first in China to deploy ultra-large scale bioreactors (5,000L) for commercial manufacturing, targeting a 70% reduction in biologics production costs through scale and process innovation (e.g., optimized 2-meter chromatography columns). Proprietary platforms include T-DC (Targeted Dendritic Cell) for targeted cancer cell therapy developed by Letu Haitu, and SEA-MAP (Single Epitope Multi-Anchor Peptide) for innovative vaccines. The company operates four CDMO/diagnostic/medical production bases — the flagship Cheerland Watson Life Technology Center in Shenzhen's Dapeng New District, a Shanghai CDMO base in Baoshan, a Shanghai Science Center in Putuo, and a small-molecule API facility in Caofeidian, Tangshan — with stated targets of 700 kiloliters total CDMO capacity by 2025 and an eventual 500,000L CMO scale.

Letu generates revenue through multiple streams: CDMO service contracts with biotech/pharma clients (professional services); molecular diagnostic testing and consumer genetic testing (subscription and fee-for-service, with 250,000+ cumulative clients served); cell storage subscriptions (capacity for over 4 million samples at the cell platform); medical services through owned outpatient clinics and the Watson Health Resort; and equity returns from a portfolio of overseas biotech investments including Compass Therapeutics, Turning Point Therapeutics, Immune-Onc Therapeutics, CRISPR Therapeutics, Synlogic Therapeutics, Guardant Health, Centrillion, twoXAR, Sentieon, Neocis, and Leaf Healthcare. Distribution combines direct enterprise sales for CDMO, direct-to-consumer channels for testing and medical services, and hospital/academic institution partnerships for clinical translation and joint research with Peking University Shenzhen Hospital, SUSTech, and Sun Yat-sen University.

Name

Letu

Legal name

深圳市乐土生命科技投资有限公司

Website

https://clbiomed.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Letu (乐土生命科技) is a Shenzhen-based precision medicine and biopharmaceutical company founded in 2016, operating a biologics CDMO platform with ultra-large scale bioreactors, molecular and consumer genetic testing, cell storage, and a high-end health resort. It serves biotech/pharma clients, cancer patients, and affluent health-conscious consumers across China.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO and Precision Medicine Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical Laboratories (621511), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Cell Therapy CDMO (HLAGABAD), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Biologics CDMO services
• Molecular diagnostic testing
• Precision medicine services
• Cell storage services
• Genetic testing services

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biologics CDMO Services: Contract development and manufacturing organization (CDMO) services for biologics including antibodies, recombinant proteins, and cell/gene therapies. Services span from DNA to IND, cell line development, drug substance manufacturing, and commercial production. Revenue is earned through service contracts with biotech/pharma companies.
2. Molecular Genetic Testing Services: Clinical and non-clinical molecular diagnostic testing including tumor testing, reproductive health testing (NIPT), and health management testing. Revenue generated from individual consumer testing and institutional/hospital contracts.
3. Medical and Healthcare Services: Medical services including precision medicine clinics, anti-aging healthcare, and medical tourism at the 乐土沃森健康会 resort. Revenue from medical services, membership fees, and healthcare packages.
4. Cell Storage Services: Stem cell and immune cell storage services covering cord blood mesenchymal stem cells, placental stem cells, dental pulp stem cells, adipose stem cells, and immune cells. Storage capacity for over 4 million samples.
5. Investment Returns / Equity: Returns from equity investments in overseas biotech companies including Compass Therapeutics, Turning Point Therapeutics, Immune-Onc Therapeutics, CRISPR Therapeutics, Synlogic Therapeutics, Guardant Health, Centrillion, twoXAR, Sentieon, Neocis, Leaf Healthcare.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Letu (乐土生命科技) is a vertically integrated precision medicine company providing Bio-CDMO contract development and manufacturing services for biologics (antibodies, recombinant proteins, cell and gene therapies) using ultra-large scale 5,000L bioreactors, alongside molecular diagnostic testing services (clinical oncology and reproductive health testing), consumer genetic testing, IVD reagent kits, cell storage and stem cell preparation services, and integrated medical services including a high-end wellness resort. The company serves both biotech/pharmaceutical enterprises (B2B CDMO) and individual consumers (B2C genetic testing and medical services) across its 700 KL planned production capacity and 4 million-sample cell storage infrastructure.

Product overview

Letu (乐土生命科技) is a precision medicine and biopharmaceutical company operating as a multi-platform portfolio. The core offerings consist of: (1) 乐土Bio-CDMO - a comprehensive contract development and manufacturing organization providing biopharmaceutical production services from DNA to IND and commercial-scale manufacturing; (2) 乐土分子检测 - molecular diagnostic testing services encompassing clinical oncology testing (lung, colorectal, breast, gynecological, liver, digestive, urinary, thyroid, glioma cancers), reproductive testing (NIPT, assisted reproduction, birth defects), and IVD reagent kits (tumor targeted drug testing, mNGS pathogen detection, COVID-19 testing); (3) Non-clinical consumer genetic testing including cancer susceptibility tests, cardiovascular risk panels, "four highs" metabolic risk testing, whole genome sequencing (WGS), children's health testing, and gut microbiome testing; (4) 乐土医疗服务 - comprehensive medical services covering precision testing, disease prevention, chronic disease management, medication guidance, and stem cell therapy; (5) 乐土沃森健康会 - a high-end medical康养旅 (medical-rehabilitation-wellness-tourism) retreat platform. The company also operates cell storage services and R&D platforms for stem cell and immune cell drug development.

Differentiator

Problem solved

Functional benefit

Brands

• 乐土CDMO: One-stop biopharmaceutical contract development and manufacturing organization (CDMO) services covering DNA to IND, cell line and drug substance services, and commercial-scale manufacturing.
• 乐土分子检测
• 乐土医疗服务
• 乐土沃森健康会
• 乐土细胞平台
• CL Biolabs

Products and services

• Letu Bio-CDMO (乐土Bio-CDMO) One-stop contract development and manufacturing organization (CDMO) services for biopharmaceuticals covering DNA to IND development, cell line development, drug substance manufacturing, and commercial-scale biologics production using ultra-large 5,000L bioreactors. Targets biotech and pharmaceutical companies needing large-scale antibody, recombinant protein, cell therapy, and gene therapy manufacturing.
• Letu Molecular Diagnostics (乐土分子检测) — Clinical Testing Services Clinical molecular diagnostic testing services covering oncology (lung cancer, colorectal cancer, breast cancer, gynecological tumors, liver and biliary tumors, digestive system tumors, urinary system tumors, thyroid tumors, glioma), reproductive health (NIPT, assisted reproduction, birth defect testing), and infectious disease. Includes development, production, and clinical testing of diagnostic reagents. Targets cancer patients, at-risk individuals, and expectant mothers through hospital channels and direct consumer purchase.
• Letu Consumer Genetic Testing (非临床检测产品) Non-clinical consumer genetic testing panels including cancer susceptibility testing for males and females, "four highs" risk testing (hypertension, hyperglycemia, hyperlipidemia, hyperuricemia), cardiovascular and cerebrovascular four-panel testing, cardiovascular disease and hypertension medication guidance, diabetes medication guidance, psychiatric and antidepressant medication guidance, epilepsy medication guidance, whole genome sequencing (WGS), children's health and development panels, gut microbiome testing, and skin type testing. Targets individual health-conscious consumers.
• IVD Reagent Kits (IVD检测试剂盒) In-vitro diagnostic reagent kits including tumor targeted drug testing kits for precision medication selection in cancer treatment, mNGS (metagenomic next-generation sequencing) pathogen detection kits for identifying infectious disease agents, and COVID-19 nucleic acid testing kits for SARS-CoV-2 detection. Distributed through clinical and laboratory channels to hospitals, diagnostic labs, and testing centers.
• Letu Medical Services (乐土医疗服务) Comprehensive medical and healthcare services delivered at owned outpatient clinics (乐土沃森综合门诊) and partner hospitals, covering precision testing, disease prevention, chronic disease management, medication guidance, and stem cell therapy. Targets patients and health-conscious consumers seeking integrated preventive and therapeutic care.
• Cell Storage Services (细胞存储服务) Stem cell and immune cell storage services covering cord blood mesenchymal stem cells, placental stem cells, dental pulp stem cells, adipose stem cells, and immune cells. Operated at GMP, AABB, and FACT-compliant facilities with over 4 million sample capacity and 10,000+ sqm of cell platform area (5,000+ sqm B-level clean areas). Targets individual consumers and families seeking biological insurance and future therapeutic use.
• Cheerland Watson Health Club (乐土沃森健康会) High-end medical康养旅 (medical-rehabilitation-wellness-tourism) retreat platform integrating medical, rehabilitation, healthcare, and tourism services. Located at Shenzhen Dapeng Peninsula. Led by Nobel Laureate Dr. James Watson's team of top scientists. Targets affluent individuals and high-net-worth families seeking premium preventive health, longevity management, anti-aging, and integrated wellness experiences.

Quantifiable outcome

• Target biologics manufacturing cost reduction of 70% through large-scale commercial production
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• 深圳市益诺思生物医药安全评价研究院有限公司coreStrategic or Co-development Partner · 8 May 2022乐土生命科技与益诺思签订合作协议，双方将共同在深圳建设国际一流的生物医药安全评价服务平台，在新药研发、工艺开发、临床前实验、生产及商业化阶段的大规模生产等领域达成全面合作。
• 旭化成医療株式会社 (Asahi Kasei Medical)minorStrategic or Co-development Partner旭化成医疗株式会社高层于2026年1月到访乐土开展深度调研与学术交流活动，探索 potential collaboration in medical and biomanufacturing areas.
• 中山大学药学院coreStrategic or Co-development Partner乐土与中山大学药学院合作共建乐土清远中大创新药物研究中心和中山大学博士后科研工作站，承接科技创新、科研项目引进与转化、人才引进等工作。
• 南方科技大学 (SUSTech)coreStrategic or Co-development Partner乐土与南方科技大学共建药学院 and 南科大乐土精准医学研究院, focusing on precision medicine research and talent cultivation.
• 北京大学深圳医院coreStrategic or Co-development Partner乐土与北大深圳医院共建北大深圳医院乐土精准医学研究院、北大深圳医院乐土门诊部 and 北大深圳医院妇产科生殖干细胞实验室, for joint research and clinical translation in precision medicine and reproductive stem cells.
• 乐土沃森慈善基金会minorOthers乐土沃森慈善基金会与美国乐土公司合作，在COVID-19疫情期间紧急组织海外采购，向红十字会捐赠现金500万元及价值数百万的医疗物资。

Scale indicators8 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• WuXi Biologics: Largest Chinese biologics CDMO operating end-to-end development, clinical and commercial manufacturing across mAbs, bispecifics and ADCs at multi-thousand-liter scales. The most direct competitor to Letu's planned 700 KL biologics CDMO platform, with a much larger customer base and approved commercial products already running through its facilities.
• Genscript Biotech (Legend Biotech): China-headquartered biotech/CDMO with significant cell therapy and gene therapy contract services, plus its own CAR-T pipeline via Legend Biotech. Comparable to Letu's biologics and cell therapy CDMO positioning and its T-DC cell therapy platform.
• Burning Rock Biotech: Leading Chinese oncology NGS / molecular diagnostics company with companion diagnostic and liquid biopsy products. Directly comparable to Letu's clinical oncology molecular testing menu (lung, breast, colorectal, glioma panels) and IVD reagent unit.
• Berry Genomics: Specialized in NIPT, reproductive health and oncology molecular diagnostics in China. Closely comparable to Letu's reproductive testing menu (NIPT, assisted reproduction, birth defects) and consumer genetic testing products.

Broad incumbents

• WuXi STA (WuXi AppTec): Integrated CRO/CDMO arm of WuXi AppTec covering both small-molecule API and biologics manufacturing. Overlaps with Letu's CDMO ambitions in biologics and competes with its Caofeidian small-molecule API base, while also providing services Letu does not yet offer (preclinical CRO, clinical CRO).
• Pharmaron: China-rooted, global CRO/CDMO offering drug discovery through commercial manufacturing for both small molecules and biologics. Comparable to Letu as a one-stop outsourcing partner but with a far broader service portfolio and established regulatory track record with global sponsors.
• Tigermed: Largest Chinese clinical CRO, expanding into biologics CDMO and investment in biotech ventures. Comparable to Letu through its clinical development arm and growing biomanufacturing footprint, though much more clinical-CRO focused than Letu's manufacturing-heavy model.
• BGI Genomics: China's largest genomic sequencing and diagnostics provider, covering NIPT, oncology testing, rare disease and infectious disease. Comparable to Letu's consumer and clinical genetic testing lines including NIPT and WGS, but at vastly greater scale and price competitiveness.

Others

• Asahi Kasei Medical: Japanese bioprocess and medical device supplier (Planova virus filters, dialysis) that visited Letu in January 2026 for collaboration discussions. Comparable as a strategic biomanufacturing ecosystem participant and a potential upstream/downstream partner for Letu's CDMO expansion.

Emerging players

• CARsgen Therapeutics: Chinese cell therapy company developing CAR-T products for hematologic and solid tumors. Comparable to Letu's T-DC targeted dendritic cell platform and immune cell drug R&D platform as a fellow emerging Chinese cell therapy player with proprietary platform technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries8 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Letu